Sebia’s sFLC Assay Validated by Mayo Clinic: A New Standard of Diagnostic Confidence

Clinical equivalence. Global credibility. Mayo Clinic approved.
Sebia’s Serum Free Light Chain (sFLC) assay has been independently validated for clinical equivalence by a leading team at the Mayo Clinic. Published in Blood Cancer Journal (2022), this pivotal study confirms that Sebia’s test matches the performance of the established Freelite® assay for the diagnosis and monitoring of multiple myeloma.

Study highlights:

• Head-to-head comparison with The Binding Site’s™ Freelite® assay, as recommended by the International Myeloma Working Group (IMWG).
• Equivalent clinical performance for the rFLC (ratio of free light chains) thresholds of >20 and >100, which are critical markers used to diagnose active multiple myeloma.
• Assay conducted on Siemens BNII analyzer, demonstrating cross-platform commutability.

What it means for clinicians:

• Confidence that Sebia’s ELISA-based sFLC assay meets diagnostic gold standards.
• The ability to adopt a cost-effective, flexible solution—without sacrificing accuracy or clinical relevance.
• Seamless alignment with IMWG criteria and ongoing multiple myeloma care protocols.

Trusted results. Proven performance. Mayo-grade validation.
With peer-reviewed, real-world evidence from the Mayo Clinic team, Sebia’s sFLC assay is positioned as a high-confidence alternative for laboratories and healthcare systems seeking robust, scalable FLC testing.

Download the article summary to learn more—or scan the QR code to access the full publication.

White Paper from   Brought to you by: